HC Wainwright Issues Negative Forecast for CervoMed Earnings

CervoMed Inc. (NASDAQ:CRVO) – Equities research analysts at HC Wainwright lowered their Q2 2026 earnings estimates for shares of CervoMed in a research report issued to clients and investors on Tuesday, May 26th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.74) per share for the quarter, down from their previous forecast of ($0.70). HC Wainwright currently has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($2.87) per share. HC Wainwright also issued estimates for CervoMed’s Q3 2026 earnings at ($0.60) EPS, Q4 2026 earnings at ($0.65) EPS, FY2026 earnings at ($2.77) EPS, Q1 2027 earnings at ($0.71) EPS, Q2 2027 earnings at ($0.61) EPS, Q4 2027 earnings at ($0.61) EPS and FY2027 earnings at ($2.48) EPS.

CervoMed (NASDAQ:CRVO) last announced its earnings results on Monday, May 18th. The company reported ($0.86) EPS for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.04. CervoMed had a negative return on equity of 136.08% and a negative net margin of 672.80%.

A number of other equities analysts have also recently commented on CRVO. raised CervoMed to a “strong-buy” rating in a report on Tuesday, February 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of CervoMed in a report on Monday, April 20th. D. Boral Capital reissued a “buy” rating and set a $31.00 target price on shares of CervoMed in a report on Wednesday, April 22nd. Chardan Capital increased their target price on CervoMed from $15.00 to $21.00 and gave the company a “buy” rating in a report on Wednesday, March 18th. Finally, Roth Mkm set a $9.00 price objective on shares of CervoMed in a research note on Monday, May 18th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.60.

CervoMed Price Performance

Shares of CervoMed stock opened at $3.04 on Thursday. The business has a 50 day simple moving average of $3.78 and a two-hundred day simple moving average of $5.70. CervoMed has a 12 month low of $2.82 and a 12 month high of $13.13. The stock has a market capitalization of $28.15 million, a P/E ratio of -0.93 and a beta of -0.63.

Hedge Funds Weigh In On CervoMed

Several institutional investors and hedge funds have recently bought and sold shares of CRVO. AQR Capital Management LLC acquired a new position in CervoMed in the 1st quarter valued at about $227,000. Rhumbline Advisers boosted its holdings in CervoMed by 35.5% in the 1st quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock valued at $53,000 after purchasing an additional 1,526 shares during the last quarter. Marshall Wace LLP acquired a new position in CervoMed in the 2nd quarter valued at about $76,000. Jane Street Group LLC acquired a new position in CervoMed in the 2nd quarter valued at about $414,000. Finally, Thompson Davis & CO. Inc. boosted its holdings in CervoMed by 20.8% in the 3rd quarter. Thompson Davis & CO. Inc. now owns 16,850 shares of the company’s stock valued at $136,000 after purchasing an additional 2,900 shares during the last quarter. 25.15% of the stock is currently owned by institutional investors and hedge funds.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.